 |
|
Drugs That Wouldn't Die
Michael Weintraub, MD;
Frances K. Northington, PhD
JAMA. 1986;255(17):2327-2328.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
MEDICAL practitioners and patients have more influence over pharmaceutical companies than they realize. In at least five instances, pressure from consumers and prescribers of medications has changed a pharmaceutical company's marketing decision. Unprofitable drugs, initially removed from the market primarily for financial reasons, were reinstated in response to medical information and intervention, with little hope of increased sales. In this report, we review five "drugs that wouldn't die" and the circumstances of their withdrawal and remarketing that demonstrate that the pharmaceutical industry will respond to patients' and physicians' needs.
The "drugs that wouldn't die" referred to above are not orphan drugs (those that would be beneficial to small populations or that are not patentable and so have limited sales potential1). These medications were initially developed for an indication with a potentially large market, but were subsequently supplanted by other therapeutic agents with respect to their primary indication. Because these
. . . [Full Text PDF of this Article]
Author Affiliations
From the Department of Preventive, Family, and Rehabilitation Medicine, University of Rochester (NY) School of Medicine and Dentistry.
Footnotes
Reprint requests to Department of Preventive, Family, and Rehabilitation Medicine, Box 644, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14642 (Dr Weintraub).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
